Bioxyne Limited announced that subsequent to the execution of a non-binding Heads of Agreement to sell its HI-164 Oral Vaccine project together with all of its Intellectual Properties (IP) to Mariposa Health Limited (MHL), Dr. Phillip Comans has stepped down as Chief Executive Officer of the company. In the interim, operational matters would be managed by the chairman, Mr. Tony Ho and the CFO Mr. Jarrod White.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.006 AUD | 0.00% |
|
+20.00% | -45.45% |
05-14 | Bioxyne to Release Shares from Escrow; Shares Up 17% | MT |
05-14 | Bioxyne Subsidiary, CY Biopharma Enter Partnership to Advance Novel Psilocybin Therapies in Australia | MT |
1st Jan change | Capi. | |
---|---|---|
-45.45% | 8.12M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- BXN Stock
- News Bioxyne Limited
- Phillip Comans Steps Down as CEO of Bioxyne Limited